晚期胆道癌患者接受吉西他滨、顺铂和白蛋白结合型紫杉醇治疗时FDG PET/CT参数的预后价值
本研究回顾性分析了125例接受吉西他滨、顺铂和白蛋白结合型紫杉醇(Gem/Cis/Nab-P)治疗的晚期胆道癌(BTC)患者,于治疗前进行FDG PET/CT显像并量化原发肿瘤的SUVmax、MTV和TLG。多因素分析显示TLG是PFS和OS的独立预后因素(P<0.05)。局部晚期且低TLG患者及胆囊癌低TLG患者可能从该方案获得更优生存获益。
要点
- 治疗前FDG PET/CT的TLG是晚期BTC患者PFS和OS的独立预后因素。
- 局部晚期且低TLG患者的中位PFS达18.4个月,中位OS未达到。
- 胆囊癌患者中低TLG组的中位PFS为11.7个月,TLG可区分PFS和OS。
核心结论
- 治疗前FDG PET/CT的TLG是晚期胆道癌患者接受Gem/Cis/Nab-P治疗后PFS和OS的独立预后生物标志物。
- 局部晚期疾病且低TLG、以及胆囊癌伴低TLG可能预测从Gem/Cis/Nab-P治疗中获得更优生存获益。
研究设计与样本
- 回顾性分析125例晚期胆道癌患者,治疗前接受FDG PET/CT显像,随后接受Gem/Cis/Nab-P治疗。
- 从PET/CT图像中量化原发肿瘤的最大标准化摄取值(SUVmax)、代谢肿瘤体积(MTV)和总病灶糖酵解(TLG),并分析这些参数对预后结局的影响。
主要发现
- 多因素生存分析确定TLG是PFS和OS的独立显著预后因素(P<0.05)。
- 按疾病分期和TLG分层分析,局部晚期且低TLG患者获得最有利的生存结局(中位PFS 18.4个月;中位OS未达到)。
- 在肿瘤亚型中,TLG可有效区分胆囊癌患者的PFS和OS,低TLG组中位PFS为11.7个月。
关键数值与推荐
- 多因素分析中TLG对PFS和OS的P值均<0.05。
- 局部晚期且低TLG患者的中位PFS为18.4个月,中位OS未达到。
- 胆囊癌低TLG组的中位PFS为11.7个月。
临床怎么用
- 对拟接受Gem/Cis/Nab-P治疗的晚期胆道癌患者,治疗前FDG PET/CT所测TLG可用于预后分层。
- 局部晚期且低TLG或胆囊癌伴低TLG的患者可能更可能从Gem/Cis/Nab-P治疗中获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although a phase 3 trial did not demonstrate a survival benefit for gemcitabine, cisplatin, and nab-paclitaxel (Gem/Cis/Nab-P) in advanced biliary tract cancer (BTC), favorable outcomes were observed in specific patient subgroups, notably those with locally advanced disease or gallbladder carcinoma (GBC). This study aimed to assess the prognostic value of FDG PET/CT-derived parameters in advanced BTC patients treated with the Gem/Cis/Nab-P regimen, thereby identifying potential PET/CT imaging biomarkers that may aid in predicting survival benefit. PATIENTS AND METHODS: We conducted a retrospective analysis of 125 advanced BTC patients who underwent pretreatment FDG PET/CT followed by Gem/Cis/Nab-P therapy. From the PET/CT images, maximum standardized uptake value, metabolic tumor volume, and total lesion glycolysis (TLG) of primary tumors were quantified. The influence of these parameters on prognostic outcomes was determined. RESULTS: Multivariate survival analysis identified TLG as an independent significant prognostic factor for both progression-free survival (PFS) and overall survival (OS) ( P <0.05). In subgroup analyses stratified by disease stage and TLG, patients with locally advanced disease and low TLG achieved the most favorable survival outcomes (median PFS, 18.4 months; median OS, not reached). Among tumor subtypes, TLG effectively differentiated PFS and OS in GBC patients, with the low TLG group exhibiting a median PFS of 11.7 months. CONCLUSIONS: TLG on pretreatment FDG PET/CT served as an independent prognostic biomarker for PFS and OS in advanced BTC. Locally advanced disease and low TLG, as well as GBC with low TLG, might be predictive of enhanced survival benefit from Gem/Cis/Nab-P therapy.
引用
- Lee JW, Lee SM, Kang B, et al. Prognostic Value of FDG PET/CT Parameters in Patients With Advanced Biliary Tract Cancer Receiving Gemcitabine, Cisplatin, and Nab-Paclitaxel. Clin Nucl Med. 2026. PMID: 41627846. doi:10.1097/RLU.0000000000006306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。